The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

GLP-1 drugs like Ozempic are injectable medications—but a strange new market has emerged selling oral “compounded” versions ...

Eli Lilly shares are down 11% since president-elect Donald Trump nominated Robert F. Kennedy, Jr. to be Secretary of Health ...

Drugmakers are likewise reaching out to other employers with the message that treating obesity will ultimately save them money.

As revolutionary new weight-loss drugs turn consumers off ultraprocessed foods, the industry is on the hunt for new products.

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 ...

Novo Nordisk has officially launched its weight-loss drug Wegovy in China after receiving approval in June. The move pits it ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound, according to the AXIACI ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...